Targeting HIV-1 conserved regions: An immunoinformatic pathway to vaccine innovation for the Asia
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317382 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Akmal Zubair und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Quaid-i-Azam University Islamabad, Pakistan. Hauptthemen laut MEDLINE: HIV-1, AIDS Vaccines, HIV Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A combination of humoral and cell-mediated immune system stimulation is essential for developing an effective HIV vaccine. Traditional treatment options and the challenges posed by drug resistance necessitate the discovery of a viable vaccine candidate capable of eliciting a robust immunological response. This research aims to develop an HIV vaccine with a multi-epitope component using a unique immunoinformatics approach. A subunit vaccine comprising B-cell, helper T-cell, and cytotoxic T-cell epitopes, along with appropriate adjuvants and linkers, was employed to identify conserved regions in the Pol, Vpr, Gag, Tat, Env, Nef, and Vif proteins. The HIV subunit vaccine demonstrated the potential to activate both cell-mediated and humoral immune responses, indicating its immunogenicity. The application of homology modeling and refinement further enhanced the model’s accuracy. Subsequently, the molecular docking procedure utilized the refined model structure to bind to the immunological receptor TLR-3 in lymphocyte cells. Following this, the potential interactions of the subunit vaccine with TLR-3 were investigated using molecular dynamics modeling. The vaccine’s stability was improved through a meticulous disulfide engineering technique that involved inserting cysteine residues into highly flexible regions. Finally, in silico cloning was employed to validate the efficacy of translating and producing the vaccine in a microbiological setting. The vaccine shows promising results in terms of population coverage, reaching 82% of the global population, with extraordinary efficacy in Asia, covering up to 95% of the population. Our HIV vaccine candidate is highly stable and elicits a robust immune response against HIV-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Quaid-i-Azam University Islamabad, Pakistan.
- Department of Pathology, College of Medicine, King Khalid University, Asir , Saudi Arabia.
- Department of Livestock Production and Management, Faculty of Veterinary and Animal Sciences PIR Mehr Ali Shah-Arid Agriculture University Rawalpindi, Shamsabad, Murree Road, Pakistan.
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
ORCID-Profile: Akmal Zubair
Zitieren
APA
Zubair, A., Al-Emam, A., Ali, M., Hussain, S. M., & Elmagzoub, R. M. (2025). Targeting HIV-1 conserved regions: An immunoinformatic pathway to vaccine innovation for the Asia. PLOS ONE. https://doi.org/10.1371/journal.pone.0317382
Vancouver
Zubair A, Al-Emam A, Ali M, Hussain SM, Elmagzoub RM. Targeting HIV-1 conserved regions: An immunoinformatic pathway to vaccine innovation for the Asia. PLOS ONE. 2025. doi:10.1371/journal.pone.0317382
BibTeX
@article{Zubair2025,
author = {Zubair, Akmal and Al-Emam, Ahmed and Ali, Muhammad and Hussain, Syeda Maryam and Elmagzoub, Ranya Mohammed},
title = {Targeting HIV-1 conserved regions: An immunoinformatic pathway to vaccine innovation for the Asia},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317382}
}
EUVIMED